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Introduction: Unliganded iron both contributes to the pathology of Alzheimer’s disease
(AD) and also changes the morphology of erythrocytes (RBCs). We tested the hypothesis
that these two facts might be linked, i.e., that the RBCs of AD individuals have a variant
morphology, that might have diagnostic or prognostic value.
Methods: We included a literature survey of AD and its relationships to the vascular
system, followed by a laboratory study. Four different microscopy techniques were used
and results statistically compared to analyze trends between high and normal serum
ferritin (SF) AD individuals.
Results: Light and scanning electron microscopies showed little difference between the
morphologies of RBCs taken from healthy individuals and from normal SF AD individuals.
By contrast, there were substantial changes in the morphology of RBCs taken from high
SF AD individuals. These differences were also observed using confocal microscopy and
as a significantly greater membrane stiffness (measured using force-distance curves).
Conclusion:We argue that high ferritin levels may contribute to an accelerated pathology
in AD. Our findings reinforce the importance of (unliganded) iron in AD, and suggest the
possibility both of an early diagnosis and some means of treating or slowing down the
progress of this disease.
Keywords: Alzheimer’s disease, erythrocytes, iron, scanning electron microscopy, atomic force microscopy
INTRODUCTION
There is increasing evidence that vascular components, including
RBCs and fibrinogen, play a fundamental role in neurologi-
cal diseases, including Alzheimer’s disease (AD) (Kovacic and
Fuster, 2012; Diomedi and Misaggi, 2013; Kling et al., 2013).
Erythrocytes (RBCs) are highly deformable, and this physical
property contributes significantly to assisting blood flow in the
microcirculation, where capillaries may be barely larger than
the nominal RBC diameter (Mohandas and Gallagher, 2008).
According to one view, the abnormalities in RBCs and their
flow contribute to AD by obstructing oxygen delivery to brain
(Tateishi et al., 2001; Mohanty et al., 2008; Tripathy et al., 2013)
that, in turn, causes hypoxia leading to a chronic inflammation
(Eltzschig and Carmeliet, 2011; Wyss-Coray and Rogers, 2012).
Mohanty and co-workers in 2010 noted that there is a potential
link between alterations in the RBC membrane proteome in AD
subjects and AD pathology (Mohanty et al., 2010). These authors
showed that 15% of RBCs in AD patients were elongated, and
that there were alterations in the RBC membrane architecture.
They suggested that this might be due to RBC-beta-amyloid inter-
actions and/or changes in the expression of membrane proteins.
Fibrinogen, a plasma precursor of fibrin has been found in the
brains of AD patients (Choi et al., 2002) and it was shown that fib-
rin also interacted with beta-amyloid protein (Merkle et al., 1996)
in such patients. There is also evidence in AD that perivascular
leakage of fibrinogen happens in AD and more importantly that
fibrin accelerates neurovascular damage (Paul et al., 2007).
Closely linked to hematological pathology in AD are increased
iron levels, that also play an important role in the pathogenesis
of the condition (Barnham and Bush, 2008; Smith et al., 2010;
Weinberg, 2010). Increased iron levels cause oxidative stress, as
they participate in oxygen-dependent free radical formation (Kell,
2009). Free radical stresses, and specifically those from hydroxyl
radicals, are important factors in the pathogenesis of AD, as they
lead to protein modification and consequently to neuronal dam-
age (Casadesus et al., 2004; Castellani et al., 2012). This free
radical stress may also impact on RBCs, and this may cause
extensive and accumulative damage to these cells, ultimately com-
promising their functioning. Optimal oxygen delivery to the brain
clearly depends on optimal RBC physiology (Tateishi et al., 2001).
Finally, here, increased RBC aggregation and sedimentation, as
well as flow abnormalities, have been observed in the blood of
patients with degenerative diseases such as atherosclerosis and
inflammation, that are also known to be associated with AD
(Robinson et al., 1995; Andresdottir et al., 2003; McMahon et al.,
2013).
We have shown previously that when iron overload is present
in conditions such as diabetes and hereditary hemochromatosis,
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RBCs are distorted, and form pointed extensions (Lipinski et al.,
2012a; Pretorius, 2013; Pretorius and Lipinski, 2013). This change
in morphology (and perhaps deformability—see below) may play
a fundamental role in the thrombotic and cardiovascular risk
typically seen in these and other conditions. In diseases such as
thalassemia and hereditary hemochromatosis (Carpenter et al.,
2013), literature also suggests the prevalence of cardiac complica-
tions (Noori et al., 2012; Maggio et al., 2013) and thrombocytosis
with increased risk of stroke (Shariat et al., 2013). Also, we have
previously shown that a changed RBC, platelet and fibrin net-
work ultrastructure is present in stroke (Lipinski et al., 2012b;
Swanepoel and Pretorius, 2012).
During wound healing and the consequent activation of
the coagulation pathway, a fibrin net is created (Weisel, 2005).
Thrombin is part of the relevant cascade that facilitates the con-
version (Undas and Ariëns, 2011), and is involved in the normal
final step that converts soluble fibrinogen to the resulting fibrin
net (Davalos and Akassoglou, 2012). Under laboratory condi-
tions, this fibrin fiber net can be simulated by adding thrombin
to either whole blood or plasma (Pretorius et al., 2013c). In
healthy individuals, these fibers form a net that lies on top of
and around the discoid RBCs. However, in the presence of iron
overload, the RBCs are folded and twisted around the fibers, sug-
gesting structural changes to these fibers and/or cells. The fibers
are also more compact, and rather than a net, form dense matted
deposits known as “atypical parafibrin” (Lipinski and Pretorius,
2013; Pretorius et al., 2013a). When physiological levels of unli-
ganded ferric iron are added to healthy whole blood, the resulting
parafibrin becomes resistant to the normal pathways of fibrin
degradation (Pretorius and Lipinski, 2013). Also, the RBCs show
the same ultrastructure as in iron overload, where they twist
around fibers. The structural changes in RBCs in the presence of
iron overload, may impact on the rheological properties of the
cells. Previously, it was noted in hereditary hemochromatosis, that
there is a higher plasma viscosity, resulting in damage to red cells
at the level of microcirculation (Ershova et al., 1998). In the light
of the compelling evidence that (i) RBCs and fibrin are changed
in iron overload, and (ii) that iron is involved in the pathogenesis
of AD, we here investigate the hypothesis that in AD, especially
in the presence of iron overload, the morphology of RBCs is also
altered significantly, and that one may contribute to the other.
Because iron is implicated in AD, serum ferritin (SF) levels
of each patient were also measured. Iron deposition in vari-
ous organs, ultimately resulting in end-organ damage, including
arthralgias, osteoporosis, cirrhosis, hepatocellular cancer, car-
diomyopathy, dysrhythmia, diabetes mellitus, and hypogonadism
(Crownover and Covey, 2013; Kanwar and Kowdley, 2013) has
been linked directly to elevated SF levels (Kanwar and Kowdley,
2013). Also, SF above 150 ng/mL−1 (females) or 300 ng/mL−1
(males) is taken as iron overload (Kellner and Zoller, 1992;
Koziol et al., 2001; Adams et al., 2005, 2006; Adams, 2008;
Jacobs et al., 2009; Gordeuk et al., 2012; Crownover and Covey,
2013). Light microscopy was used to study the general mor-
phology of the erythrocytes, and their axial ratios were mea-
sured to determine variation in shape. Also, scanning electron
microscopy (SEM) analysis of RBCs was performed to deter-
mine interactions between erythrocytes and fibrin. Furthermore,
the presence of spontaneous hypercoagulability, visible as dense
matted fibrin deposits (DMDs), and ultrastructural erythro-
cyte membrane changes were also studied. The deformabil-
ity of the cell membranes was determined using atomic force
microscopy (AFM). Finally, confocal microscopy was used to
study the permeability of erythrocyte membranes to a partic-
ular dye, to assess the presence of membrane damage. Overall,
we found that many AD patients have an increased SF level,
and that the RBCs of these individuals differed significantly in
both ultrastructural properties and membrane elasticity, as well
as in terms of membrane permeability, from those taken from
healthy as well as those from AD individuals with normal SF
levels.
Thus, in the current work we studied the blood of 25 AD
patients and of 40 healthy individuals. This manuscript is struc-
tured as follows (see Figure 1, based on the desirability of an
overview figure (Wong, 2011): we start with a literature survey of
AD and its relationships to the vascular system, particularly the
role of RBCs. Then we assessed the SF levels in AD patients. We
used four different microscopy techniques to study whole blood
from AD patients and compared these to samples taken from
healthy individuals. Finally we correlated the microscopy results
with SF levels in our AD individuals.
MATERIALS AND METHODS
VOLUNTEER DETAILS
Bloods were obtained from fully diagnosed Alzheimer’s patients.
All donors so designated had been diagnosed with AD by qualified
medical practitioners and did not smoke. Specifically, a neurolo-
gist diagnosed all AD individuals that included the patient history,
as well as the Mini Mental State Examination (MMSE) (Table 1
shows their history and SF levels, while Table 2 shows the sum-
mary characteristics of the sample. While the average age and
gender balance differed between controls and AD patients, they
were well matched between low-SF and high-SF AD patients,
which is what is of interest here). A recent study suggested that
there are increased markers of iron deposition (including SF lev-
els) and oxidative stress in patients with cognitive dysfunction
(Umur et al., 2011). Furthermore, the authors suggested that it
seems likely that these markers had a negative effect on theMMSE
score (Smith et al., 2010; Bartzokis et al., 2011; Umur et al.,
2011; Penke et al., 2012). Ethical clearance was obtained from the
Health Sciences Ethical committee from the University of Pretoria
and informed consent was obtained from family members who
act as guardians of the patients. Healthy individuals also filled in
consent forms.
Blood (6mL) was collected in a citrate tube and also 6mL
were collected in a tube for serum iron level determination. The
AD patients were divided into two groups (normal and high SF
levels, high “high SF” being defined as a level of >150 ng·mL−1
for females and 300 ng·mL−1 for males). Healthy individuals
were identified and they also did not smoke or have any chronic
conditions, their ages varied from 19 to 79. Ethical approval
was granted at the University of Pretoria (HUMAN ETHICS
COMMITTEE: FACULTY OF HEALTH SCIENCES) under the
name J. Bester. Written informed consent was obtained from
all healthy individuals used as controls. Written consent was
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FIGURE 1 | An overview figure summarizing the contents of this
manuscript. (1) Literature suggests that there is a rationale for looking at the
vascular system and particularly blood; (2) our sample was chosen to be a
random group of Alzheimer’s individuals (AD), as well as healthy individuals;
(3) (unliganded) iron has been implicated in the literature as a role player in
AD; serum ferritin levels were measured; (4) our methodologies included
various microscopy techniques; (5) finally we correlated our microscopy
results to the presence of high serum ferritin levels.
obtained from a family member who is responsible for the care
of each AD individual.
LIGHT MICROSCOPY AND AXIAL RATIOS
Thin LM smears were made followed by air-drying, fixing
in methanol, and staining with Methylene blue and Eosin
(Copenhaver et al., 1971). Slides were mounted with Entellan
and viewed with a Nikon Optiphod transmitted light micro-
scope (Nikon Instech Co., Kanagawa, Japan). Axial ratios of RBCs
from 40 healthy individuals, as well as the two AD groups were
captured using ImageJ (ImageJ is a public domain, Java-based
image processing program developed at the National Institutes
of Health: http://rsbweb.nih.gov/ij/). Axial ratios were always
greater than (or equal to) 1 by using the largest diameter
overall as the numerator, and as the denominator the length
at 90◦ to the line used to provide the numerator. On aver-
age, 20 RBCs were assessed for each individual. A box plot,
which is a descriptive statistical method (and other statistics)
were calculated using MS-Excel, together with the add-in tem-
plate downloadable from http://www.vertex42.com/. P-values
were calculated from the means, the numbers of objects mea-
sured in each class and the standard deviations using the Excel
add-in available via http://www.talkstats.com/attachment.php?
attachmentid=261&d=1213281245 and the facility at http://
www.graphpad.com/quickcalcs/ttest1.cfm?Format=SD.
SCANNING ELECTRON MICROSCOPY (SEM)
After the blood was collected, 10µl of whole blood were placed
directly on a glass cover slip, fixed, dehydrated, dried, mounted
and coated with carbon according to previously described meth-
ods (Buys et al., 2013). Additionally, 10µl of whole blood (WB)
wasmixed with 5µl of thrombin, to create an extensive fibrin net-
work in between the RBCs. A Zeiss ULTRA Plus FEG-SEM with
InLens capabilities was used to study the surface morphology of
erythrocytes, and micrographs were taken at 1 kV.
ATOMIC FORCE MICROSCOPY (AFM)
WB in a citrate tube was centrifuged at 145× g for 30 s. The super-
natant (plasma, platelets, and white blood cells) were discarded
and the remaining RBC’s were prepared for AFM by fixing in
4% formaldehyde (made up in PBS) for 30min, at room tem-
perature (22◦C) followed by dehydration and placing a drop of
the RBC’s suspended in undiluted (161.39 g/mol) hexamethyld-
isilazane (HMDS) onto a glass cover-slip and spreading the fluid
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Table 1 | Serum ferritin levels (SF) of Alzheimer’s (AD) patients,
history and corresponding figure numbers.
AD individual
gender and age
AD diagnosed in years
and previous medical
conditions
SF
(ng·mL−1)
Corresponding
figure
AD WITH NORMAL SF
F; 74 4; previous thrombotic
stroke
49 Figure 3
F; 59 6; epilepsy 58
F; 91 10; Osteoporosis 32
F; 85 3; none 17
F; 67 1.5; high blood pressure 130 Figure 2 (4);
Figure 6C (4)
F; 76 13; hypothyroidism 94 Figure 6B (3)
F; 83 3; hypothyroidism 57 Figure 2 (3)
F; 93 13; hypothyroidism; 3
heart attacks
128 Figure 6B (2)
F; 80 12; hypothyroidism; high
blood pressure
29 Figure 2 (1)
F; 67 8; high blood pressure;
high cholesterol
101 Figure 2 (2);
Figure 6B (1)
AD WITH HIGH SF
M; 60 1; high cholesterol 359
F; 84 10; kidney atrophy 302 Figures 4B,C
F; 96 2; none 256 Figure 2 (3)
F; 77 2; asthma; high blood
pressure; osteoporosis
173 Figure 2 (2)
F; 76 7; high cholesterol 194 Figure 6C (2)
M; 74 4; depression 311 Figure 6C (4)
M; 80 15; thrombotic stroke;
high blood pressure
187
F; 85 3; none 189
F; 93 3; hypothyroidism; heart
bypass
240 Figure 2 (4)
F; 88 4; hypothyroidism, high
blood pressure;
osteoporosis
153
F; 89 10; high blood pressure 300 Figure 4A
F; 86 9; high blood pressure 244 Figure 6C (3)
F; 78 10; none 423
F; 75 8; high blood pressure 371 Figure 2 (1);
Figure 6C (1)
F; 80 7; back problems 196
by tilting the coverslip sideways, ensuring an even distribution of
cells. Cover slips were dried and stored until AFM analysis.
Characterization of the cells was performed with a com-
mercial AFM system (Dimension Icon with ScanAsyst, Bruker,
USA) using the PeakForce QNM (Quantitative Nanomechanical
Property Mapping) imaging mode. This method is similar to the
standard tapping mode of scanning probe microscopy, where the
probe and the sample are brought together intermittently, but in
contrast to the more classical tapping mode (where the oscillation
amplitude is kept constant), this mode operates by controlling
the maximum force applied by the probe to the sample (Dufrêne
et al., 2013). At every pixel a rapid force-distance curve is per-
formed and as the cantilever’s deflection sensitivity and spring
constant is calibrated before measurements, the curve can be ana-
lyzed quantitatively to obtain a series of specific property maps
of the sample (Figure 2). Thus, the retract curve is used to cal-
culate modulus and adhesion images (slope of the curve and the
minimum of the curve, respectively), the variation between the
zero and maximum force is used to calculate deformation and
the area between the approach and retract curve can be used to
calculate energy dissipation (Berquand, 2011; Kolar et al., 2013).
Thus, the retract curve is used to calculate modulus and adhe-
sion images (slope of the curve and the minimum of the curve,
respectively), the variation between the zero and maximum force
is used to calculate deformation, also energy dissipation can be
measured as tip-sample interactions cause hysteresis between the
approach and retract curves and by measuring the area between
these curves the loss of mechanical energy can be determined.
The Young’s modulus is a measure of the stiffness of an elas-
tic material and can generally be defined as stress divided by
the corresponding strain, with greater values indicating increased
stiffness or decreased deformability. As each force curve’s data
can also be stored individually, it is possible to obtain quan-
titative measurements of the Young’s modulus by fitting the
slope of any force distance curve of the image to an appropriate
model (in this instance; the Derjaguin–Muller–Toporov (DMT)
Model (Derjaguin et al., 1975). Silicon Nitride probes (TAP525—
MPP 13120-10, Bruker, USA) with a nominal force constant of
200N·m−1, a resonant frequency between 430 and 516 kHz (mea-
sured by the manufacturer), and a nominal tip radius of 15 nm
were employed in all AFM measurements. Ten cells from a min-
imum of 7 individuals out of each group (see Table 3) were
analyzed by selecting a 1µm by 1µm scan area on the periphery
of the RBC and performing 128 by 128 data points of individ-
ual force curve measurements with a peak force of 6µN. The
periphery of the cells was chosen as there might be differences
in concavity of RBCs, and we therefore chose an area that is not
affected by the concavity of the specific RBC. The scans were per-
formed at 0.6Hz, which translates to a tip velocity of 1.2µm·s−1
and 25–35 force curves were chosen randomly within the stated
area. Offline software (NanoScope Analysis version R3, Bruker,
USA) was used to process the force curves and fit the modulus
model to the unloading portion (red curve, using the green sec-
tion marked in Figure 2 of the “retraction” curve). The goodness
of fit (R2) between the modulus model and the data given by the
acquired curve is determined by calculating the ratio of explained
variation to total variation in the dataset; only force curves with a
goodness of fit so defined of 0.85 and above were used for mod-
ulus measurements. The statistical significance of the difference
between calculations was determined using one-way analysis of
variance. A P-value of less than 0.05 relative to the null hypothesis
was considered to be “significant” [cf. (Broadhurst and Kell,
2006)], and P-values are noted.
CONFOCAL MICROSCOPY
Confocal microscopy was used to determine if membrane dam-
age could be detected using a specific membrane marker.
Unfortunately, there is a limited availablilty of specific mark-
ers for RBCs and their membranes. We identified the use of
LIVE/DEAD Fixable Dead Cell Stain from Life Technologies™ as
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Table 2 | Summary characteristics of healthy individuals and Alzheimer’s disease individuals.
Healthy individuals (n = 40) Normal serum ferritin
AD individuals (n = 11)
High serum ferritin AD
individuals (n = 14)
Average age and range 26, 19–79 78, 59–91 81, 60–96
Average number of years suffering from
Alzheimer’s disease and range
0 8, 2–15 6, 1–10
Male: female 22:18 1:10 2:12
Serum ferritin levels and range < 150 ng·mL−1 for females and
300ng·mL−1 for males
80, 17–187 265, 154–423
Smoker: non-smoker 0:40 0:11 1:13
Etiology ischemic/non-ischemic 0:40 2:9 0:14
Hypertensive: Normotensive 0:40 4:7 5:9
ACE-inhibitors: yes/no 0:40 4:7 3:11
Beta-blockers: yes/no 0:40 1:10 1:13
Hypothyroid: yes/no 0:40 4:7 2:12
Hypercholesterolemia: yes/no 1:39 1:10 2:12
Anti-coagulant: yes/no yes/no 0:40 1:10 1:13
Asthma: yes/no 0:40 0:11 1:13
Epilepsy: yes/no 0:40 1:10 0:14
Osteoporosis: yes/no 0:40 1:10 1:13
Normal SF females: 10–150 ng·mL−1; males: 12–300 ng·mL−1; Normal ranges for low density lipoprotein (LDL) < 1.8 mmol·L−1; high density lipoprotein: >
1.6 mmol/L; total cholesterol < 5.2 mmol·L−1; ischemic vs. non-ischemic: individual had at least 1 thrombotic event in his/her lifetime; non-ischemic: no thrombotic
event; normal blood pressure: 80/120 mmHg. Hypothyroidism: thyroid stimulating hormone (TSH) > 5.5 µIU/mL.
FIGURE 2 | Schematic representation of force/separation plot
illustrating the type of the information that can be obtained [adapted
and redrawn from Berquand (2011)].
a possible marker for membrane damage. This stain kit is based
on the reaction of a fluorescent reactive dye with intracellular and
extracellular amines. The reactive dye can permeate membranes
compromised before fixation and react with free amines both in
the interior and on the cell surface, resulting in intense fluorescent
staining (Perfetto et al., 2010). In viable cells, only the exterior
cell-surface amines are available to react with the dye, resulting
in relatively dim staining. The influence of cell type and marker
specificity on the stability of fluorescence intensity after fixation
has not been well studied and fluorescence stability should be
determined for each cell type and marker used (Stewart et al.,
2007). Therefore, we optimized the method specifically to use
Table 3 | Descriptive statistics for elasticity (MPa) of red blood cell
(RBC) membranes as obtained from the atomic force microscopy
(AFM).
Analysis Control High SF AD Normal SF AD
Mean 46,711 53,465 45,706
Standard deviation 39,211 49,711 45,473
Standard error 750 1228 788
P-value (vs. control) – 6.6·10−7* 0.3
N (individuals) 11 7 10
P-value (high SF AD vs.
normal SF AD)
4.4·10−8*
N (cells) 110 72 100
N (curves) 2737 1639 3331
*Significant p-value.
blood fixed and stored in 4% formaldehyde. For this, we used
fresh and fixed blood (4% formaldehyde) of three healthy indi-
viduals, as well as of an individual with high SF levels diagnosed
with hemochromatosis (SF = 33000 ng·mL−1). Before we added
the dye, we washed the fixed samples, 3× with PBS to eliminate
formaldehyde residues. No difference in fluorescence intensity
was noted between the fixed and fresh samples, except that the
fluorescence faded within a minute in the fresh samples.
In the current study, the RBCs were fixed and stored in 4%
formaldehyde. When confocal microscopy was done, the cells
were washed 3× in PBS and vortexed to form a pellet. 100µl of
RBCs was then re-suspended in 100µl PBS. 0.2µl of LIVE/DEAD
Fixable Dead Cell Stain (from Life Technologies) was added to
20µl RBCs in PBS and incubated at room temperature, in the
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dark for 20min. 5µl of the sample were mounted and viewed
using a Zeiss LSM 510 META confocal microscope with a Plan-
Apochromat 63×/1.4 Oil DIC objective with wavelengths of
488 nm and 514 nm. Confocal micrographs were analyzed using
the ImageJ fluorescence measuring function, where we deter-
mined the level of fluorescence. We calculated the corrected total
cell fluorescence (CTCF) for each patient and then the mean for
each of the 3 groups. This is done with the following formula:
CTCF = mean integrated density− (mean area of selected cells X
mean fluorescence of background readings).
RESULTS
Table 1 shows the outline medical history of the AD individuals,
as well as their SF levels, while Table 2 shows statistical summary
characteristics. None of the individuals was considered (as dis-
cussed with their neurologist) to have major health complications
that might bias the analysis. Figure 3 shows the axial ratios of
the erythrocytes, depicted as box plots, together with descriptive
statistics. There are no significant shape difference between the
erythrocytes of controls and of those taken from AD individu-
als with normal levels of SF, however, there are highly significant
differences between the axial ratios of both control vs. high SF
AD individuals and between the axial ratios of the erythrocytes
of normal SF and of high SF AD individuals. Figure 4 shows
light microscopy smears of four healthy individuals and also four
normal and four high SF AD individuals. In these micrographs,
healthy individuals show the typical discoid RBC shape. This is
also seen in the normal SF AD individuals. However, a large
fraction of the RBCs of the high SF AD individuals have an
elongated, non-discoid RBC shape, as previously seen for erythro-
cytes taken from individuals with iron overload (Pretorius and
Lipinski, 2013).
Analysis of RBCs using SEM (Figures 5–7) confirmed the LM
results, and showed that the RBCs of normal SF AD individuals
FIGURE 3 | Box plots and descriptive statistics of the axial ratios of
erythrocytes of healthy individuals and of Alzheimer’s patients (AD)
with normal or high serum ferritin (SF) levels. There were no significant
difference between the axial ratios of RBCs of healthy individuals and those
of normal SF AD patients (p = 0.099), however, there were significant
differences between the axial ratios of erythrocytes from normal SF AD
patients vs. those of high SF AD patients (p = 1.07·10−11) and between
those of healthy individuals and those from high SF AD patients
(p = 1.84·10−35).
typically have a discoid shape, and appear no different from the
RBCs of healthy individuals. When thrombin is added to whole
blood of healthy individuals, the RBCs retain their discoid shape
(Figure 5B) (Pretorius, 2013); the same was found for whole
blood from the normal SF AD patients (Figure 6B). However,
when looking at the RBCs of high SF AD individuals, these were
seen to form pointed extensions and to have a slight elongation
(in WB smears); this was also noted in LM smears (Figures 4,
6A,B). Also, in the presence of fibrin fibers, generated after addi-
tion of thrombin, the RBCs fold around the fibers (Figure 7D),
and areas of thickened and matted fibrin or DMDs are also noted
(Figure 7D). This changed fibrin ultrastructure, where fibrino-
gen coagulates to formmatted plates rather than individual fibrin
fibers (that were also thinner), has previously been noted in both
thrombo-embolic ischemic stroke and diabetes (Lipinski et al.,
2012b; Buys et al., 2013), as well as in the presence of exogenously
added unliganded Fe(III) (Pretorius et al., 2013c).
High (150,000×) SEM magnifications of RBC membranes
show that the membrane surface of healthy cells has a typi-
cal globular structure (Pretorius, 2013; Pretorius et al., 2013b)
(Figure 5C); this was also found for normal SF AD individuals
(Figure 6C). The membranes of RBC from high SF AD individu-
als were more granular, when studied at 150,000× magnification
(compare Figures 6C, 7C). This implies that themembrane archi-
tecture is changed and that possibly the elasticity and membrane
integrity might be compromised. Therefore, because significant
changes in membrane ultrastructure were seen when viewed at
very high SEM magnification, we were interested to see if these
changes were accompanied by any other alterations in the RBC
membrane, which may result in changed mechanical properties
of the cell.
Force-distance curves [see (Dufrêne et al., 2013) and above],
and subsequent modulus value calculations, were used to assess
this. Elastic modulus calculations (Table 2) showed that the
Young’s modulus of RBCs taken from high SF AD individuals
(53,465MPa) is statistically significantly higher than the Young’s
FIGURE 4 | Light microscopy smears of (A) four healthy individuals and
(B) four normal and (C) four high normal serum ferritin (SF) Alzheimer’s (AD)
individuals. Scale = 5 µm.
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FIGURE 5 | Scanning electron microscopy (SEM) micrographs of a typical
healthy red blood cell (scale = 1 µm) (A). RBC that is discoid in shape when
thrombin is added to whole blood (scale = 1µm) (B); high magnification of
RBC membrane, showing globular structure; (C) (Scale = 100nm).
modulus values observed in control and normal SF AD RBCs
(46,711 and 45,706MPa, respectively). This ca 15% increase in
the Young’s Modulus, meaning there is a decrease in elastic-
ity, can also be seen directly in the typical force-distance curves
(Figure 8), where a steeper slope and decreased probe displace-
ment of the high SF RBC curve is evident.
Because the changes in mechanical stiffness of the RBCs of AD
patients with high SFmight reasonably be expected to be reflected
in changes in other membrane properties, we then sought to
assess the membrane permeability of the different RBC (before
fixation) using a so-called LIVE/DEAD Fixable Dead Cell Stain.
The LIVE/DEAD Fixable Dead Cell Stain can bind to amines on
the outer membrane of the cell but when membrane integrity
is compromised it may enter the cell to bind to amines typ-
ically found inside the cell. When this happens, the damaged
cells will show a higher green fluorescence. To compare confo-
cal microscopy data of RBCs from healthy individuals with those
from individuals with AD and normal and high SF, we show
micrographs from six individuals in each of the three groups
(Figure 9). Confocal microscopy showed that there is substan-
tially higher fluorescence intensity in RBCs from the high SF AD
individuals relative to that in RBCs taken from the controls or
the normal SF AD individuals. Analysis of confocal micrographs
with ImageJ showed the CTCF for each of the groups. A t-test
was performed at 5% level of significance (i.e., where a P = 0.05
is considered as significant). On this basis, there is no significant
FIGURE 6 | Red blood cell from a normal SF AD individual (scale = 1 µm)
(A); where thrombin is added to whole blood; the cells keep their discoid
shape (scale = 1 µm) (B); high magnification of RBC membrane, showing
globular structure (Scale = 100nm) (C).
difference between the CTCF of healthy individuals vs. that of
normal SF AD individuals (p = 0.89), however, there is a signif-
icant difference between the CTCF of healthy individuals and of
high SF AD patients (0.04) as well as between normal SF and high
SF AD individuals.
To determine if there is any correlation between the sever-
ity of the disease manifestations and other variables, we graded
the light microscopy smears independently (Table 4). We used
three stages, namely normal discoid shape (N, typically seen in
healthy individuals), slightly affected (S), and severely affected
(A). There was no especially obvious relationship between the
morphological grades and either the age at onset or the duration
of the Alzheimer’s. However, the SF levels were noticeably greater
as the cells moved from grades N (67 ± 35 ng·mL−1, mean ±
SD) through S (202 ± 91 ng·mL−1) to A (280 83 ± ng·mL−1).
Visualizations were also performed using the Tibco/Perkin Elmer
Spotfire software, where the trends once again showed that the
severity of the RBC changes are clearly linked to the SF levels
(Figure 10).
DISCUSSION
Iron overload is associated with many pathological conditions,
including liver and heart diseases, neurodegenerative disorders,
diabetes, hormonal abnormalities immune system abnormalities,
heart failure, and in particular in the more classical condi-
tions recognized as “iron overload” diseases such as hereditary
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FIGURE 7 | Scanning electron microscopy (SEM) micrographs of a typical
high serum ferritin (SF) Alzheimer’s (AD) individual (scale = 1 µm) (A,B).
High machine magnification (150,000×) of a typical RBC membrane from a
high serum ferritin (SF) Alzheimer’s (AD) individual (Scale = 100nm) (C); red
blood cell from a high serum ferritin (SF) Alzheimer’s (AD) individual where
thrombin is added to whole blood; the cells loose their discoid shapes and
dense matted fibrin deposits are present in the lower left corner of the
micrograph (indicated by arrows) (scale = 1µm) (D).
FIGURE 8 | Force-Distance curves obtained on RBCs from healthy
individuals, normal serum ferritin (SF) Alzheimer’s (AD) individuals
and high serum ferritin (SF) Alzheimer’s (AD) individuals.
Force-Distance curves show the atomic force microscope (AFM) cantilever
deflection range on the platelet surface.
hemochromatosis, where iron overload is caused by a specific
genetic mutation (Kwan et al., 1998; Shizukuda et al., 2006, 2007;
Kell, 2009, 2010; Camaschella and Poggiali, 2011; Crichton et al.,
2011; Castellani et al., 2012; Finberg, 2013; Funke et al., 2013;
Martines et al., 2013; Pretorius et al., 2013a,c; Tsuchiya and Nitta,
2013). Many workers have suggested that increased iron lev-
els are also associated with cardiovacular events by facilitating
oxidative stress, and that iron-induced vascular dysfunction may
contribute to the increased incidence of ischemic cardiovascular
events (Corti et al., 1997; Horwitz and Rosenthal, 1999; Anderson
et al., 2001; Day et al., 2003; Kondur et al., 2009; Zegrean, 2009;
Zhao et al., 2010; Meroño et al., 2011; Zacharski et al., 2011;
Rajapurkar et al., 2012). Poorly liganded iron is the main culprit
and plays a fundamental role in the development of pathology
(Kell, 2009, 2010). Moderate iron overload is also known to accel-
erate thrombus formation after arterial injury, increases vascular
oxidative stress, and impairs vasoreactivity (Day et al., 2003).
The main kind of mechanism by which iron overload causes tis-
sue damage is considered to be free radical toxicity caused by
the excessive levels of the (poorly liganded) metal (Jomova and
Valko, 2011; Barton et al., 2012; Ferro et al., 2012; Pra et al., 2012;
Crownover and Covey, 2013). Hydroxyl radicals (OH ·) are espe-
cially well-known culprits in causing damage to biomolecules,
and iron catalyzes the redox-based production of hydroxyl radi-
cals via the Fenton reaction (Goldstein et al., 1993; Wardman and
Candeias, 1996; Aisen et al., 2001; Kell, 2009, 2010; Rival et al.,
2009; Khechaduri et al., 2013).
Previously, we have shown that RBCs are very sensitive to
unliganded iron changes, and that physiological levels of ferric
iron, added to WB, cause shape changes in RBCs (Lipinski et al.,
2012a; Pretorius and Lipinski, 2013). These shape changes are
also present in hereditary hemochromatosis, as well as in cases
of hyperferritinemia where the genetic mutation underpinning
HH is not present (Pretorius et al., 2013a,b,c, in press). There
are four iron measurements that medical practitioners typically
will request when iron overload is suspected. They are SF, serum
iron, serum transferrin and% transferrin saturation (Brandhagen
et al., 2002; Limdi and Crampton, 2004). Serum iron is the
amount of circulating iron bound to transferrin; transferrin binds
iron and controls the level of free iron in biological fluids.
Optimal saturation should be between 20 and 45% [% transferrin
binding sites that should be filled (McCullen et al., 2002; Limdi
and Crampton, 2004; Daniels, 2010)]. We have indicated previ-
ously, that SF levels are the iron-related value that most effectively
imply or reflect iron overload (Pretorius et al., 2013a,b,c, in press);
and this view is reflected in the literature (Kellner and Zoller,
1992; Koziol et al., 2001; Adams et al., 2005, 2006; Adams, 2008;
Jacobs et al., 2009; Gordeuk et al., 2012; Crownover and Covey,
2013)]. In the current study, we used SF levels as an indication of
iron overload in our AD patient group. SF levels above approx-
imately females 150 ng/mL−1 and males 300 ng/mL−1 was taken
as implying iron overload (Kellner and Zoller, 1992; Koziol et al.,
2001; Adams et al., 2005, 2006; Adams, 2008; Jacobs et al., 2009;
Gordeuk et al., 2012; Crownover and Covey, 2013).
Inside cells, ferritin is the major iron storage protein, with 24
subunits forming a cage around up to 4500 iron atoms (Lu et al.,
2013). However, the method of ferritin excretion into serum,
and what it is that is secreted (just the protein shell subunits, or
the entire ferritin molecule) that then degrades liberating iron,
remains poorly understood. Ferritin concentrations in serum
reflect the iron store of the body (Cook et al., 1974; Hori et al.,
2010). Although ferritin itself may protect against oxidative stress
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FIGURE 9 | Confocal microscopy of RBCs from (A) four healthy individuals, (B) four normal serum ferritin (SF) Alzheimer’s individuals (AD) and (C) four high SF
AD individuals. Scale = 10 µm.
Table 4 | Alzheimer’s disease patient data, showing duration and age of onset and serum ferritin (SF) levels, as well as severity of changes,
indicated as normal discoid morphology, slightly affected and severely affected shape changes.
Gender Age at onset of AD Duration in years SF (ng/mL−1) Discoid shape Slightly affected Significantly affected
F 70 4 49 x
F 80 3 58 x
F 82.5 2.5 17 x
F 65.5 1.5 130 x
F 63 13 94 x
F 53 6 58 x
F 68 12 29 x
F 59 8 101 x
M 59 1 360 x
F 81 10 32 x
F 75 2 173 x
F 69 7 194 x
M 70 4 311 x
M 65 15 187 x
F 82 3 189 x
F 80 13 128 x
F 77 9 244 x
F 74 10 302 x
F 94 2 256 x
F 90 3 240 x
F 84 4 153 x
F 79 10 300 x
F 68 10 423 x
F 67 8 371 x
F 73 7 196 x
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FIGURE 10 | Alzheimer’s disease as a function of serum ferritin for
normal (blue) slightly (green) or strongly affected (red) morphologies.
Also displayed are gender (females circles, males squares), and duration in
years (via the size of the symbols).
by chelating free iron (Torti and Torti, 2002), it can also be a
mediator of oxidative stress by releasing free iron (Reif, 1992).
Thus, despite its clear usefulness as a clinical tool to assess body
iron stores, much of the pathophysiology of SF remains vague.
We have, however, come to the conclusion that SF is a good bio-
marker, as it is widely used in diagnosing and monitoring iron
overload diseases (Adams, 2008;Wang et al., 2010). This would be
consistent with a view that the levels of SF do reflect unliganded
iron that has been liberated during or following its secretion.
Where high SF levels are present in the AD individuals, and
when thrombin is added to WB, the RBCs deform and twist
around the resulting fibrin fibers (Figure 6D). In the current
study we compared RBCs of AD individuals with normal and high
SF levels to RBCs taken from healthy individuals. Interestingly,
we found that RBCs from the normal SF AD individuals still keep
their discoid shape. Also, when thrombin is added toWB, the cells
still appear discoid when entrapped in the resulting fibrin fiber
network. However, when we study RBCs from high SF AD indi-
viduals, their RBCs have a somewhat more elongated shape. This
is seen in LM, as well as SEM micrographs (Figures 2, 3).
We also confirm previous results that suggest that fibrin is
altered in AD and it was also shown that fibrin interacts with
beta-amyloid protein (Merkle et al., 1996; Choi et al., 2002). Also,
literature suggests that fibrinogen can bind iron (Orino, 2013)
and that this might be pertinent to the correlation between high
ferritin and aberrant fibrin morphology as seen in Figure 7D.
We confirmed that high SF AD RBCs have an increased
Young’s modulus, and therefore decreased elasticity as seen from
the AFM results. This finding is in line with previous research
that reported increased Young’s modulus values in pathologi-
cal RBCs (Dulinska et al., 2006) and living cells (Müller et al.,
2009). Although the cells in the aforementioned study were
only briefly fixed and followed by analysis in fluid, other stud-
ies have shown that variances in elasticity of different types of
dried Jurkat cells (Cai et al., 2009) and RBCs (Jin et al., 2010;
Dufrêne et al., 2013; Picas et al., 2013) can be detected. We
suggest that the RBC deformability in AD with high SF levels
may be due to membrane and cytoskeletal architectural changes
and that this might be the reason why the cells have lost their
ability to maintain or return to their discoid shape in the pres-
ence of fibrin fibers. Continuous and unobstructed delivery of
oxygen to the brain via the RBCs, depends on their membrane
fluidity (Tateishi et al., 2001). RBCs are highly deformable and
elastic, and this physical property contributes significantly to aid-
ing blood flow in the microcirculation (Baskurt and Meiselman,
2003; Mohandas and Gallagher, 2008). Furthermore, research
suggests that blood rheology is altered in various pathophysio-
logical conditions. The extent of deformability may be affected
by, amongst others, alterations of the properties and associa-
tions of membrane skeletal proteins (Koshino et al., 2012). If
RBCs have optimal functioning, their ability to deform improves
blood flow in the micro-vessels at high shear rate (Shin et al.,
2007), and membrane architecture also plays an important role
in the mechanical stability of the cells in the presence of shear
forces (Nans et al., 2011). Baines in 2009 suggested that the
elasticity of RBCs depends on the dynamic rearrangement of
spectrin dimers/tetramers under the shearing forces experienced
in circulation (Baines, 2009); and that stable intact helical linker
regions are needed to maintain the soft elasticity of spectrin
(Mirijanian and Voth, 2008). A decreased deformability is also
seen in inflammatory conditions such as diabetes (Shin et al.,
2007); a spatial reorganization of the cytoskeleton was also noted
in this condition (Starodubtseva et al., 2008). A reduced plas-
ticity in cerebral ischemia (Kowal, 1996) and increase stiffness
was also noted in conditions like coronary disease and hyper-
tension (Lekka et al., 2005). It therefore seems as if a decreased
deformability and increase in stiffness is common in inflamma-
tory disease, and can be ascribed to a changed elasticity as well
as stability. Therefore, the changed elasticity seen in the current
study, will impact on the membrane fluidity and deformability
of the cell as it moves through the circulation. This may result
in atypical tissue perfusion, leading to functional deteriorations,
ultimately resulting in disturbed vascular properties (Baskurt and
Meiselman, 2003). Confocal microscopy confirmed that RBCs
from high SF AD individuals have structural membrane dam-
age, in that the probe assessed enters the cell membrane and
binds to the amines inside the cell, causing a bright fluorescence
in the cells of this group. The bright fluorescence was present
to a much lesser degree in RBCs taken from the normal SF AD
individuals or the controls, and here only a dull fluorescence
was seen, suggesting that as expected the dye reacts only with
to the amines on the outer membrane. Statistical analyses con-
firmed that there was a significant difference between the CTCF
of RBCs from healthy and high SF AD individuals, while there
were no significant difference between the CTCF of RBCs from
healthy individuals vs. normal SF AD individuals. Grading of the
severity of the changes (Table 4 and Figure 10), confirms that the
SF levels are well correlated with the severity of the RBC shape
changes.
CONCLUSION
Despite many years of AD research, we still do not know the
best strategies to treat this very debilitating condition, and its
likely multifactorial aetiology could be taken to suggest that we
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need a multi-modal treatment regime [e.g., (Kupershmidt et al.,
2012a)]. In the current study we were surprised to find that
60% of our randomly chosen AD population had increased SF
levels. Although we have shown in the introductory paragraphs
that there is extensive literature suggesting that iron levels have
been closely associated with AD pathology and might exacerbate
pathology in these patients (see above), iron levels in AD patients
are not seen as a compulsory pathology test (personal communi-
cations with neurologists treating AD patients), notwithstanding
literature indicating the relevance of ferritin dysregulation to
AD [e.g., (Connor et al., 1992; Quintana et al., 2006; Friedman
et al., 2011; Giambattistelli et al., 2012; De Sole et al., 2013)].
Importantly, our findings support the literature regarding dys-
regulated iron metabolism, as 60% of our sample shows high
SF levels. We show that RBC ultrastructure is changed signifi-
cantly in the presence of iron overload (as judged by SF). We
have demonstrated this with 4 different techniques and statisti-
cal analysis confirms this. These changes might impair the oxygen
carrying capacity and compromise hemorheology of the RBCs,
and additionally cause a strain on the already challenged brain
function of these individuals. It seems as if iron overload might
be present in AD patients more widely than generally believed.
Indeed, iron overloadmight cause the condition to progress faster
than in AD individuals who do not have iron overload, particu-
larly due to the additional hydroxyl radical load. The substantial
differences in the RBCs, of high-SF AD patients might suggest
that some of the minimally invasive measurements we have per-
formedmight be of diagnostic significance, while the potential for
chelating or liganding iron might have some therapeutic benefits
[as first shownmore than 20 years ago (Crapper McLachlan et al.,
1991) and more recently (Kupershmidt et al., 2012b)]. We con-
clude by recommending that AD patients should be screened for
iron overload and that, when it is present, a comprehensive treat-
ment regime be implemented to monitor and indeed decrease
iron levels throughout the progression of this very debilitating
condition.
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